Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nabriva therapeutics appoints CEO

This article was originally published in Scrip

Executive Summary

Biotechnology company Nabriva Therapeutics, which is developing a new class of antibiotics for the treatment of serious infections caused by resistant gram-positive and gram-negative pathogens, has named Dr Colin Broom chief executive officer. Prior to joining Vienna-based Nabriva Dr Broom was chief scientific officer at ViroPharma, which was acquired by Shire in January 2014. He succeeds Ralf Schmid, who will remain at the company as a member of the executive management team and will move to the role of chief financial officer and chief operating officer.

You may also be interested in...



A Backstage View Of Roche’s Recent Collaborations

In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.

Fact File: Coronavirus Medtech And Diagnostic Updates

As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.

Making Progress Against Rare Diseases

Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.

Related Companies

UsernamePublicRestriction

Register

SC026242

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel